Compounded Bioidentical Hormone Therapy: Identifying Use Trends and Knowledge Gaps Among US Women

JoAnn V. Pinkerton, MD; Nanette Santoro, MD


Menopause. 2015;22(9):926-936. 

In This Article


As many as 1 million to 2.5 million US women may be taking CHT. Many women seem not to distinguish between CHT products and FDA-approved medications and may be unaware of the inadequacy of medical evidence supporting CHT use or unaware of reported concerns with the quality and safety of CHT. Our data suggest that women turn to their physician for advice when considering HT for menopausal symptoms. Providers can play a pivotal role in helping women understand the different levels of evidence supporting the efficacy, safety, and quality of CHT versus FDA-approved HT and the differences in FDA regulation and monitoring between compounded and approved drugs.